公司拥有抗体偶联物(ADC)、融合蛋白与双抗三大技术平台,2021 年上市的维迪西妥单抗(爱地希)为首款国产ADC,融合蛋白泰它西普(泰爱)为全球首款双靶点治疗系统性红斑狼疮的生物药,两款产品为国内肿瘤与自身免疫领域的明星产品。公司在肿瘤与眼科领域拥有六款在研药物,研发管线强大。首款国产ADC 维迪西妥单抗销售收入将快速增加ADC 兼具抗体类药物的高标靶性与化学药物的强杀伤力,近年需求快速增加。维...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.